Related Experiment Video

Updated: Sep 20, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
10:55

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

Published on: October 31, 2025

Fatal interstitial pulmonary fibrosis in anti-Jo-1-negative amyopathic dermatomyositis

Whitney A High1, Jack B Cohen, Bettina A Murphy

  • 1Department of Dermatology, University of Texas Sothwestern Medical Center, Dallas, Texas 75390-9190, USA.

Journal of the American Academy of Dermatology
|August 2, 2003
PubMed

Insights

Amyopathic dermatomyositis, a form of skin inflammation without muscle issues, can lead to fatal interstitial pulmonary fibrosis. This case highlights a risk even in patients negative for the common anti-Jo-1 antibody.

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Amyopathic dermatomyositis (DM) is characterized by skin manifestations without overt muscle weakness.
  • Interstitial pulmonary fibrosis (IPF) is a known complication of DM, frequently associated with antisynthetase antibodies like anti-Jo-1.
  • The anti-Jo-1 antibody is a key biomarker in antisynthetase syndrome, often linked to DM-associated lung disease.

Observation:

  • This report details a rare case of a patient presenting with amyopathic DM.
  • The patient developed fatal IPF.
  • Crucially, the patient tested negative for the anti-Jo-1 antibody.

Findings:

  • The study identifies a fatal case of interstitial pulmonary fibrosis in a patient with amyopathic dermatomyositis.
  • This finding is significant as the patient was negative for the anti-Jo-1 antibody, a common marker for DM-related lung disease.
  • It suggests that IPF can occur in amyopathic DM independently of anti-Jo-1 seropositivity.

Implications:

  • This case expands the understanding of potential complications in amyopathic DM.
  • It highlights the need to consider IPF in amyopathic DM patients even without anti-Jo-1 antibodies.
  • Further research may be warranted to identify other potential autoantibodies or risk factors for IPF in this patient subset.

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining, normally used to...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...